Marker Therapeutics

Houston, Texas, United States · Biotechnology · 29 employees

Marker Therapeutics is a clinical-stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform.

Funding history

Funding Round — $16.1M — Dec 2024
Series seed — $3.1M — May 2018
Funding Round — $6.2M — Jun 2017
Series seed — $3.1M — Sep 2016
Series seed — $2.4M — Aug 2016

Recent signals

Dec 30, 2024: Raised $16.1M
May 24, 2018: Raised $3.1M in Series seed
Jun 29, 2017: Raised $6.2M
Sep 09, 2016: Raised $3.1M in Series seed
Aug 23, 2016: Raised $2.4M in Series seed

See plans & pricing → Track Marker Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.